Romosozumab efficacy and safety in European patients enrolled in the FRAME trial

SUMMARY: In this post hoc analysis, we assessed romosozumab efficacy and safety in European patients enrolled in FRAME. Romosozumab treatment through 12 months, followed by denosumab for a further 24 months, resulted in early and sustained risk reduction for major fracture categories, associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Langdahl, Bente, Hofbauer, Lorenz C., Ferrari, Serge, Wang, Zhenxun, Fahrleitner-Pammer, Astrid, Gielen, Evelien, Lakatos, Péter, Czerwinski, Edward, Gimeno, Esteban Jódar, Timoshanko, Jen, Oates, Mary, Libanati, Cesar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652294/
https://www.ncbi.nlm.nih.gov/pubmed/36173415
http://dx.doi.org/10.1007/s00198-022-06544-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652294/
https://www.ncbi.nlm.nih.gov/pubmed/36173415
http://dx.doi.org/10.1007/s00198-022-06544-2

Ejemplares similares